The Fast-Evolving Landscape of Treatments for Calcium Pyrophosphate Deposition Disease
Gout, Urate, and Crystal Deposition Disease · 25.11.2025 · 3 (4) · 22
DOI: 10.3390/gucdd3040022 ↗Kurz gefasst
Fachartikel in der Zeitschrift Gout, Urate, and Crystal Deposition Disease, online erschienen am 25.11.2025. Verfasst von Vicky Tai und 3 weiteren Autor:innen. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Health Research Council of New Zealand.
Abstract (Originalsprache)
Calcium pyrophosphate deposition (CPPD) disease is a consequence of the immune response to the pathological accumulation of calcium pyrophosphate (CPP) crystals within joints. This clinically heterogeneous condition can cause significant disability, yet its management remains poorly defined. New discoveries are reshaping the therapeutic landscape beyond conventional anti-inflammatory agents—which remain the cornerstone of care—justifying this review on current standard of care and treatment advances in CPPD disease. We first address the two theoretical management goals, namely inflammation control and crystal dissolution—with attempts to address the latter having failed thus far. We then summarize the evidence supporting conventional anti-inflammatory treatments and review insights into the pathophysiology of CPPD disease, which are driving the development of novel therapeutic strategies. These include the current use of biologics (IL-1 and IL-6 inhibitors) to control inflammation and highlight the need to explore new pathways to inhibit crystal formation (e.g., selective NPP1 blockers). We present the treatments in the development pipeline for CPPD disease (including JAK inhibitors), and the therapies currently undergoing clinical trials in gout for which findings could be extended to CPPD disease given their shared pathophysiology (e.g., NLRP3 inhibitors). To support and improve research on CPPD disease treatments, clinical trial design needs to be standardized, incorporating the recent ACR/EULAR classification criteria for accurate diagnosis, careful phenotypic stratification to ensure homogeneous patient groups (although this point requires consensus), and validated core outcome domains currently being developed by the OMERACT.
Förderung
- Health Research Council of New Zealand
Zitieren
APA
Tai, V., Jauffret, C., Dalbeth, N., & Pascart, T. (2025). The Fast-Evolving Landscape of Treatments for Calcium Pyrophosphate Deposition Disease. Gout, Urate, and Crystal Deposition Disease, 3(4), 22. https://doi.org/10.3390/gucdd3040022
Vancouver
Tai V, Jauffret C, Dalbeth N, Pascart T. The Fast-Evolving Landscape of Treatments for Calcium Pyrophosphate Deposition Disease. Gout, Urate, and Crystal Deposition Disease. 2025;3(4):22. doi:10.3390/gucdd3040022
BibTeX
@article{Tai2025,
author = {Tai, Vicky and Jauffret, Charlotte and Dalbeth, Nicola and Pascart, Tristan},
title = {The Fast-Evolving Landscape of Treatments for Calcium Pyrophosphate Deposition Disease},
journal = {Gout, Urate, and Crystal Deposition Disease},
year = {2025},
volume = {3},
number = {4},
pages = {22},
doi = {10.3390/gucdd3040022}
}
EUVIMED